Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922451 · ClinicalTrials.gov registry record
Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support
A clinical trial, sponsored by Boston Children's Hospital.
- Terminated
- Registry status
- 4
- Enrollment target
NCT03922451 is a clinical trial that was terminated before completion, run by Boston Children's Hospital. The registered enrollment target is 4 participants.
The verdict
NCT03922451 was terminated before completion, sponsored by Boston Children's Hospital.
- TERMINATED
- Registry status
- 4 participants
- Enrollment target
Study Summary
This study will measure plasma concentrations of piperacillin-tazobactam and cefazolin in pediatric patients supported with extracorporeal membrane oxygenation (ECMO) aiming to better understand the pharmacokinetics of these medications in this in vivo setting.
Interventions
- DRUG Cefazolin
- DRUG piperacillin-tazobactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-08-27 |
| Est. Completion | 2022-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03922451
The ClinicalTrials.gov registry entry for NCT03922451 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cefazolin is the first listed.
NCT03922451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03922451 about?
NCT03922451 is a clinical study titled "Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support". This study will measure plasma concentrations of piperacillin-tazobactam and cefazolin in pediatric patients supported with extracorporeal membrane oxygenation (ECMO) aiming to better understand the pharmacokinetics of these medications in this in vivo setting.
What is the current status of trial NCT03922451?
This trial is currently terminated. The enrollment target is 4 participants. The study started on 2019-08-27. Estimated completion is 2022-02-28.
What interventions are being tested in trial NCT03922451?
The interventions under investigation include: Cefazolin (DRUG), piperacillin-tazobactam (DRUG).
Who is sponsoring clinical trial NCT03922451?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.